Blueprint Medicines Corporation (BPMC)

The chart shows the growth of $10,000 invested in Blueprint Medicines Corporation in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $23,042 for a total return of roughly 130.42%. All prices are adjusted for splits and dividends.

Blueprint Medicines Corporation had a return of -0.75% year-to-date (YTD) and -32.46% in the last 12 months. Over the past 10 years, Blueprint Medicines Corporation had an annualized return of 11.16%, outperforming the S&P 500 benchmark which had an annualized return of 8.50%.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Blueprint Medicines Corporation Sharpe ratio is -0.53. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Blueprint Medicines Corporation. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Blueprint Medicines Corporation is 69.50%, recorded on Feb 24, 2023. The portfolio has not recovered from it yet.

Current Blueprint Medicines Corporation volatility is 43.30%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.